Opko Health, Inc
OPKO Health is a U.S.-based biopharmaceutical and diagnostics company with operations spanning pharmaceutical development, commercial products, laboratory testing, and product licensing. Its business includes international pharmaceutical platforms, a U.S. diagnostics laboratory business through BioReference, and partnerships that generate royalties, milestones, and other intellectual property-related revenue.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical, specialty, women’s health, and urology testing offered through BioReference.
Marketed drug products and related international pharmaceutical operations.
Revenue from intellectual property, partner royalties, and contract milestones.
Research-stage assets, collaborations, and other non-core revenue items.
Tuotteet
Raportoitu · osuus liikevaihdosta- Services61,0 %
- Products25,9 %
- Transfer of Intellectual Property and Other13,1 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
OPKO sells to physicians, hospitals, clinics, geneticists, correctional health facilities, and other healthcare providers that order diagnostic tests for patient care. On the pharmaceutical side, its customers and counterparties include patients, healthcare providers, distributors, and commercial partners that license or commercialize its products and intellectual property.
Order diagnostic tests such as 4Kscore and specialty lab panels to support diagnosis and treatment decisions.
Use laboratory services for clinical chemistry, pathology, and women’s health testing.
Influence reimbursement and network access for laboratory testing services.
License OPKO’s assets, pay royalties, and fund development or commercialization milestones.
Ultimately receive the diagnostic and therapeutic benefit from tests and medicines, though purchasing is usually mediated by providers and payors.
Strategia
OPKO’s strategy centers on combining diagnostics, commercial pharmaceuticals, and partner-driven intellectual property revenue to diversify its business base. It also relies on international pharmaceutical platforms and collaborations to extend the reach of products such as Somatrogon while using BioReference to maintain a U.S. diagnostics franchise.
Specialty tests can deepen physician relationships and support differentiated lab volumes.
Royalties and milestones provide non-lab revenue tied to external commercialization success.
Foreign operating platforms broaden product access and create commercial scale outside the U.S.
Pipeline progress can create future product revenue and licensing opportunities.
Maantiede
Q1/2026OPKO has a U.S. diagnostics footprint, with BioReference serving physicians and facilities nationwide and women’s health and clinical testing concentrated in New York and New Jersey. Its pharmaceutical operations are international, with principal platforms in Spain, Ireland, Chile, and Mexico, and research and development facilities in the United States, Ireland, Israel, and Spain.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
OPKO faces reimbursement pressure, competitive intensity, and regulatory risk across both diagnostics and pharmaceuticals. Its business also depends on successful product development, partner commercialization, patent protection, and the performance of international operations, which adds foreign exchange and impairment risk.
- Reimbursement pressure and payor consolidationVaikutus: KorkeaTodennäköisyys: Korkea
Large insurers can demand lower fees, narrower networks, or risk-sharing terms for lab services.
Kohdistuu: BioReference and clinical testing
- Quality and laboratory performance riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Errors in testing can lead to patient harm, lawsuits, reputational damage, and regulatory scrutiny.
Kohdistuu: Diagnostics operations
- Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Product development depends on FDA and other regulatory approvals and ongoing compliance.
Kohdistuu: Pipeline and marketed products
- Impairment risk on goodwill and intangiblesVaikutus: KorkeaTodennäköisyys: Kohtalainen
Large acquired intangible balances depend on future cash flow assumptions and product performance.
Kohdistuu - Competitive pressureVaikutus: KeskitasoTodennäköisyys: Korkea
Larger pharma and diagnostics peers have greater resources, scale, and commercialization reach.
Kohdistuu: Both pharmaceuticals and diagnostics
- Foreign exchange and international operating riskVaikutus: KeskitasoTodennäköisyys: Matala
International subsidiaries and foreign-currency exposure can affect reported revenue and cost of sales.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätDifferent contract types can recognize revenue at different times, affecting quarter-to-quarter comparability.
Vaikutus: BARDA contract revenue, NGENLA royalties, and commercial milestones
Large acquired balances are tested against future cash flows and can produce material write-downs if assumptions weaken.
Vaikutus: Diagnostics goodwill, Ireland reporting unit goodwill, IPR&D
International subsidiaries and foreign-currency-denominated costs can move reported revenue and margins.
Vaikutus: Chile, Mexico, Spain, and Ireland operations
Some commitments are contingent or uncapped, making liabilities and future cash needs harder to estimate.
Vaikutus: Contractual obligations and royalty agreements
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Upstream Bio, Inc.
UPB · Pharmaceutical Preparations
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
PERRIGO Co plc
PRGO · Pharmaceutical Preparations
Perrigo Co plc is a consumer self-care company focused on over-the-counter health and wellness products sold through retail and pharmacy channels.
Cosmos Health Inc.
COSM · Wholesale-Drugs, Proprietaries & Druggists' Sundries
OnKure Therapeutics, Inc.
OKUR · Pharmaceutical Preparations
Oklo Inc.
OKLO · Electric Services
Päivitetty: 24.9.2026